Pacer Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History

Pacer Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$193.33 - $291.99 $7,153 - $10,803	37 Added 21.76%	207 $57,000
Q1 2024 May 10, 2024	BUY	$171.37 - $283.23 $29,132 - $48,149	170 New	170 $45,000
Q2 2021 Jul 21, 2021	SELL	$97.2 - $137.59 $63,763 - $90,259	-656 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$108.54 - $125.2 $35,818 - $41,316	-330 Reduced 33.47%	656 $77,000
Q4 2020 Jan 20, 2021	BUY	$110.06 - $133.7 $16,509 - $20,055	150 Added 17.94%	986 $110,000
Q3 2020 Oct 19, 2020	BUY	$99.78 - $124.21 $83,416 - $103,839	836 New	836 $99,000
Q4 2018 Feb 13, 2019	SELL	$94.77 - $215.54 $102,162 - $232,352	-1,078 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $223,469 - $323,734	1,078 New	1,078 $231,000

338

22.7M

757K

960K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.77B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.